Drug Trial Radar · NCT04542070
A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed
Last checked: Nov 19, 2026Latest source record: Jun 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
687
Actual
Start
Nov 9, 2020
Primary completion
Jul 13, 2022
Study completion Apr 17, 2023
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Janssen, LP
- First posted
- Sep 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of Gilead Sciences.
Conditions
- HIV Infections
Interventions
Cabotegravir TabletsDrug
CAB tablets were available as film coated tablets for oral administration.
Cabotegravir Injectable Suspension (CAB LA)Drug
CAB LA was available as sterile suspension for injection in GSK1265744 for administration as IM injection.
Rilpivirine TabletsDrug
RPV was administered as tablets for oral administration.
Rilpivirine Injectable Suspension (RPV LA)Drug
RPV LA was available as a sterile suspension of RPV to be administered as an IM injection.
BIKTARVY Tablets (BIK)Drug
BIK was a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Plasma Human Immunodeficiency Viruses (HIV)-1 Ribonucleic Acid (RNA) Greater Than or Equal to (>=) 50 Copies Per Milliliter (c/mL) at Month 12/11 - ITT-E PopulationTime frame: At month 12/11
- Percentage of Participants With Plasma HIV-1 RNA Greater >=50 Copies Per Milliliter (c/mL) at Month 12/11 - mITT-E PopulationTime frame: At month 12/11
Locations
117 sites in 14 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Beverly Hills, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Palm Springs, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Ft. Pierce, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Pensacola, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Kansas City, Kansas
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Southfield, Michigan
GSK Investigational Site
Newark, New Jersey
GSK Investigational Site
Syracuse, New York
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Durham, North Carolina
GSK Investigational Site
Greensboro, North Carolina
GSK Investigational Site
Greenville, North Carolina
GSK Investigational Site
Huntersville, North Carolina
GSK Investigational Site
Wilmington, North Carolina
GSK Investigational Site
Toledo, Ohio
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Bellaire, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Seattle, Washington
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.